Literature DB >> 33832018

[Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China].

.   

Abstract

Year:  2021        PMID： 33832018     DOI： 10.3760/cma.j.cn112147-20201109-01091

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN： 1001-0939


× No keyword cloud information.
  4 in total

1.  Plasma concentrations of Colistin sulfate in a patient with septic shock on extracorporeal membrane oxygenation and continuous renal replacement therapy: a case report.

Authors:  Danyang Peng; Fan Zhang; Pin Lv; Yinyin Chen; Jianxu Yang; Wenliang Zhu; Shichao Zhu; Huanzhang Shao
Journal:  Ann Transl Med       Date:  2022-05

2.  Population Pharmacokinetics of Colistin Sulfate in Critically Ill Patients: Exposure and Clinical Efficacy.

Authors:  Xu-Ben Yu; Xiao-Shan Zhang; Ye-Xuan Wang; Yu-Zhen Wang; Hong-Min Zhou; Fang-Min Xu; Jun-Hui Yu; Li-Wen Zhang; Ying Dai; Zi-Ye Zhou; Chun-Hong Zhang; Guan-Yang Lin; Jing-Ye Pan
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

3.  Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients.

Authors:  Yue-Liang Xie; Xin Jin; Shan-Shan Yan; Cui-Fang Wu; Bi-Xiao Xiang; Hui Wang; Wu Liang; Bing-Chang Yang; Xue-Fei Xiao; Zhi-Ling Li; Qi Pei; Xiao-Cong Zuo; Yue Peng
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

4.  Commentary: Population pharmacokinetics of colistin sulfate in critically ill patients: Exposure and clinical efficacy.

Authors:  Huadong Chen; Piaopiao Li
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.